Method for preparing pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound

Patent metadata

Field	Value
Publication number	US-10966964-B2
Application number	US-201716080086-A
Country	US
Kind code	B2
Filing date	Feb 28, 2017
Priority date	Mar 1, 2016
Publication date	Apr 6, 2021
Grant date	Apr 6, 2021

Abstract

The present invention provides a method for preparing a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt thereof. Specifically, the invention provides a preparation method of a pharmaceutical composition, the method containing: mixing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof with at least one filler, and then granulating the mixture. The pharmaceutical composition of the invention features a rapid dissolution and good stability.

First claim

What is claimed is:

1. A method for preparing a pharmaceutical composition, comprising:
1) mixing together by weight of the total pharmaceutical composition:
a) 10-20 wt % of 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof,
b) 30-80 wt % of lactose or mannitol;
c) 5-50 wt % of pregelatinized starch;
d) 1-30 wt % of a disintegrant, wherein the disintegrant is at least one selected from the group consisting of croscarmellose sodium, sodium carboxymethyl starch, low substituted hydroxypropyl cellulose and crospovidone; and
e) 0.5-5 wt % of a lubricant, wherein the lubricant is at least one selected from the group consisting of magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide, and talc to form a mixture;
2) dry granulating the mixture to form dry granules; and
3) tableting the dry granules into tablets or filling the dry granules into capsules,
wherein the 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or the pharmaceutically acceptable salt thereof has a particle size distribution range d(0.9) of less than 60 μm.

2. The method for preparing the pharmaceutical composition according to claim 1 , wherein the composition has a dissolution rate greater than or equal to 80% in 45 minutes, wherein the dissolution rate is determined according to the second method of general rule 0931 of volume IV of Chinese Pharmacopoeia 2015 Edition, and wherein the method uses purified water as a dissolution medium at 37±0.5° C. and at a paddle speed of 50 rpm.

3. The method for preparing the pharmaceutical composition according to claim 1 , wherein the mannose or lactose is present in an amount of 50%-80% by weight, relative to the total weight of the composition.

4. The method for preparing the pharmaceutical composition according to claim 1 , wherein the disintegrant is crospovidone.

5. The method for preparing the pharmaceutical composition according to claim 1 , wherein the lubricant is magnesium stearate, colloidal silicon dioxide or a combination thereof.

6. The method for preparing the pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, malate, hydrobromide, p-toluenesulfonate, methanesulfonate, sulfate, and ethanesulfonate.

7. The method for preparing the pharmaceutical composition according to claim 1 , wherein the 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or the pharmaceutically acceptable salt thereof is present in an amount of 13.3%-20% by weight, relative to the total weight of the composition.

8. The method for preparing the pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a tablet.

9. The method for preparing the pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a capsule.

10. The method for preparing the pharmaceutical composition according to claim 1 , wherein the particle size distribution range d(0.9) is less than 40 μm.

11. The method for preparing the pharmaceutical composition according to claim 1 , wherein the disintegrant is present in an amount of 1-20% by weight, relative to the total weight of the composition.

12. The method for preparing the pharmaceutical composition according to claim 1 , wherein the lubricant is present in an amount of 1.5% by weight, relative to the total weight of the composition.

13. The method for preparing the pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable salt is malate.

Assignees

• Jiangsu Hengrui Medicine Co

Inventors

• Lu Yun
• Zhang Xinhua
• Wang Chenyang
• Liu Tonghui

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/437 Primary

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61K9/1623

  Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title